| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLRC2 |
| Uniprot No | P26717 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 94-231aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMIPFLEQ NNFSPNTRTQ KARHCGHCPE EWITYSNSCY YIGKERRTWE ESLLACTSKN SSLLSIDNEE EMKFLASILP SSWIGVFRNS SHHPWVTING LAFKHKIKDS DNAELNCAVL QVNRLKSAQC GSSMIYHCKH KL |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLRC2(NKG2C)重组蛋白的参考文献示例(注：部分文献信息为示例性概括，实际引用时请核实原文准确性)：
---
1. **"Structural analysis of the NKG2C/CD94 receptor complex using recombinant protein expression"**
**作者**: Braud, V.M., et al.
**摘要**: 本研究通过重组表达KLRC2(NKG2C)与CD94的异源二聚体，解析其与HLA-E的相互作用机制。利用表面等离子共振技术(SPR)证实重组蛋白对HLA-E的亲和力，并揭示其依赖pH的构象变化，为NK细胞免疫识别提供结构基础。
2. **"Functional characterization of recombinant KLRC2 in cytomegalovirus-specific NK cell responses"**
**作者**: López-Botet, M., et al.
**摘要**: 通过构建可溶性KLRC2重组蛋白，研究其在巨细胞病毒(CMV)感染中增强NK细胞活化的功能。实验表明，重组KLRC2与HLA-E结合后促进NK细胞脱颗粒，提示其在适应性免疫中的潜在治疗价值。
3. **"Development of a recombinant KLRC2-Fc fusion protein for modulating NK cell activity"**
**作者**: Zhang, Y., et al.
**摘要**: 报道一种KLRC2-Fc融合蛋白的哺乳动物细胞表达系统，纯化后验证其生物活性。该重组蛋白可阻断HLA-E与天然受体的结合，为研究NK细胞信号通路及肿瘤免疫治疗提供工具。
4. **"Crystal structure of the KLRC2 extracellular domain reveals ligand-binding motifs"**
**作者**: Petrie, E.J., et al.
**摘要**: 解析KLRC2胞外域重组蛋白的晶体结构，揭示其与CD94及HLA-E相互作用的关键氨基酸残基。研究为设计靶向NKG2C受体的免疫调节药物提供结构依据。
---
**说明**：以上文献为基于领域知识的示例，实际研究中请通过PubMed、Web of Science等数据库检索最新或经典文献，并核对作者、标题及摘要的准确性。KLRC2重组蛋白的研究多集中于其与配体互作机制、NK细胞功能调控及疾病治疗应用等领域。
KLRC2. also known as NKG2C, is a C-type lectin-like receptor encoded by the Killer Cell Lectin-Like Receptor Subfamily C, Member 2 (KLRC2) gene. It is primarily expressed on natural killer (NK) cells and a subset of CD8+ T lymphocytes. This transmembrane protein forms a heterodimer with CD94 (KLRD1) to create the CD94/NKG2C receptor complex, which specifically recognizes the non-classical MHC class I molecule HLA-E. HLA-E presents peptides derived from other MHC class I leader sequences, linking NKG2C-mediated signaling to cellular stress and pathogen infection.
The KLRC2-CD94 receptor plays a critical role in immune surveillance by regulating NK cell activation. Engagement of HLA-E triggers inhibitory or activating signals depending on associated adaptor proteins (DAP12 for activation). KLRC2 is notable for its association with cytomegalovirus (CMV) infection, where persistent viral exposure drives the expansion of adaptive NKG2C+ NK cells, suggesting its involvement in immunological memory formation. This property has sparked interest in KLRC2+ NK cells for cancer immunotherapy and antiviral therapies.
Recombinant KLRC2 protein is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural integrity. It serves as a vital tool for studying receptor-ligand interactions, NK cell education mechanisms, and HLA-E-mediated immune modulation. Researchers utilize KLRC2 recombinant proteins in surface plasmon resonance (SPR) binding assays, functional NK cell activation studies, and therapeutic antibody development. Recent applications include engineering chimeric antigen receptors (CARs) and investigating genetic polymorphisms linked to viral susceptibility and autoimmune diseases.
Quality-controlled batches are characterized by SDS-PAGE, Western blotting, and functional validation using HLA-E tetramer binding assays. As research progresses, KLRC2 recombinant proteins continue to provide insights into NK cell biology and precision immunotherapies.
×
